Gritstone Bio, other biotech companies are building drug pipelines with PIPEs - San Francisco Business Times

  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 40 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 68%

United States News News

United States United States Latest News,United States United States Headlines

How $GRTS and other public biotech companies are quietly raising chunks of capital from select investors PIPEs

While Wall Street largely backs away from the industry, Bay Area biotech companies have scored deals with targeted investors that in the past few months alone have quietly raised more than $100 million.

The moves come as the market for initial public offerings in the life sciences is down 90% year-over-year and about 200 newer public companies nationally are trading below the cash they hold. At the same time, fewer deals and less cash are finding private, early-stage, venture capital-backed companies.

The Oct. 25 announcement pushed Gritstone's stock from $2.23 per share that morning to $2.43 at the next day's opening, a 9% increase. Gritstone's PIPE came out of individual investors approaching the company, understanding the company's work on the Covid program and foreseeing the first mid-stage clinical trial data in fourth-quarter 2023 with its lead cancer drug program targeting individual markers on the cells of metastatic colorectal cancer patients.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 78. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United States United States Latest News, United States United States Headlines